Vivimed Labs Limited

Climate Impact & Sustainability Data (2013-14, 2014-03-31, 2020-21, 2021-22)

Continued sponsorship of new year’s lunch at Devnar School for the Blind in Hyderabad
Support to the Ankoli Tribal Middle School in Adilabad, Telangana
Eye camp at Adilabad, Telangana

Leveraged technology to connect virtually with the 637 member Vivimed team. Senior leadership spoke with the team to allay apprehensions. HR team connected with the entire team at regular intervals to explain the Dos and Don'ts during the pandemic for the health of the individual and his family. HR team worked zealously to keep the team engaged and motivated. Knowledge-sharing sessions and regular training sessions were organised virtually to enhance skill sets and personality development.

COVID-19 pandemic impacting human life extensively across the globe. Slowdown across economies. Supply chain disruptions, immobility of the sales force, delayed product launches and suspension of drug trials. Reduced business volumes and increased pressure of cost inflation.

Pharmaceutical industry being part of the essential commodities was given special permission by Indian government to operate with minimal manpower and maintaining social distancing. The Company has followed the guidelines issued by the Government to run the operations with complete cautious approach about the health and safety of the employees.
Discussions around monetising non-performing assets and utilise the funds generated to reduce the organisation’s leveraged position and fuel our growth drivers.

Annual sports and games were conducted across the organization to enhance the competitive spirit and encourage bonding teamwork among the employees.

The Company is committed to maintain the highest standards of corporate governance and adhere to the corporate governance requirements set out by Securities and Exchange Board of India (SEBI).

The cascading impacts of scaling inflation in India and across the globe inflated our cost structures.
The price erosion in the pharmaceutical space in the US was incredibly intense.
We experienced certain operational issues that impacted our ability to capitalise on all growth opportunities.
The cost of continuing our API operations through our international facilities was proving unviable – it was taking a toll on business profitability and stability.

Divestment from the API space.
Sharpened focus on expanding our formulation product basket and regional presence.
Initiated commercial supplies of formulation to Canada, Dominican Republic, Azerbaijan and Uzbekistan.
Plans for the expansion of the unit are in progress which will target new geographies & product portfolios.